Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 5, 2010, Pages 2411-2417

  Dastjerdi, Mohammad H ^a,b,c   Saban, Daniel R ^a,b   Okanobo, Andre ^a,b,c   Nallasamy, Nambi ^a,b   Sadrai, Zahra ^a,b   Chauhan, Sunil K ^a,b   Hajrasouliha, Amir R ^a,b   Dana, Reza ^a,b,c  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; CORNEA TRANSPLANTATION; DRUG EFFECT; DRUG EFFICACY; GRAFT REJECTION; GRAFT SURVIVAL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REMISSION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CONJUNCTIVA; DISEASE MODEL; DRUG ANTAGONISM; PATHOLOGY; RISK FACTOR; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CONJUNCTIVA; CORNEAL NEOVASCULARIZATION; CORNEAL TRANSPLANTATION; DISEASE MODELS, ANIMAL; GRAFT SURVIVAL; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77952514423     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-3745     Document Type: Article

References (43)

1. Coster DJ, Williams KA. The impact of corneal allograft rejection on the long-term outcome of corneal transplantation. Am J Ophthalmol. 2005;140(6):1112-1122.
2. 2007 Eye Banking Statistical Report. Washington, DC: Eye Bank Association of America; 2007.
3. Collaborative Corneal Transplantation Studies Research Group. The collaborative corneal transplantation studies (CCTS): effectiveness of histocompatibility matching in high-risk corneal transplantation. Arch Ophthalmol 1992;110(10):1392-1403.
4. Maguire MG, Stark WJ, Gottsch JD, et al. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies: Collaborative Corneal Transplantation Studies Research Group. Ophthalmology. 1994;101(9):1536-1547.
5. Williams KA, Roder D, Esterman A, et al. Factors predictive of corneal graft survival: report from the Australian Corneal Graft Registry. Ophthalmology. 1992;99(3):403-414.
6. Williams KA, Esterman AJ, Bartlett C, et al. How effective is penetrating corneal transplantation? Factors influencing long-term outcome in multivariate analysis. Transplantation. 2006;81(6):896-901.
7. Hamrah P, Djalilian A, Stulting R. Immunologically high-risk penetrating keratoplasty. In: Krachmer JH, Mannis MJ, Holland EJ, eds. Cornea. 2nd ed. Philadelphia: Elsevier Mosby; 2005.
8. Volker-Dieben HJ, D'Amaro J, Kok-van Alphen CC. Hierarchy of prognostic factors for corneal allograft survival. Aust N Z J Ophthalmol. 1987;15(1):11-18.
9. Yatoh S, Kawakami Y, Imai M, et al. Effect of a topically applied neutralizing antibody against vascular endothelial growth factor on corneal allograft rejection of rat. Transplantation. 1998;66(11): 1519-1524.
10. Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci. 2004;45(8):2666-2673.
11. Shi W, Gao H, Xie L, Wang S. Sustained intraocular rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits. Invest Ophthalmol Vis Sci. 2006;47(8):3339-3344.
12. Bachmann BO, Bock F, Wiegand SJ, et al. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol. 2008;126(1): 71-77.
13. Bachmann BO, Luetjen-Drecoll E, Bock F, et al. Transient postoperative VEGF-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation. Br J Ophthalmol. 2009;93(8):1075-1080.
14. Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci. 1996;37(12):2485-2494.
15. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004;113(7): 1040-1050.
16. Maruyama K, Ii M, Cursiefen C, et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest. 2005;115(9):2363-2372.
17. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1(1):27-31.
18. Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound-and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39(1): 18-22.
19. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;41(9):2514-2522.
20. Pieramici DJ, Rabena MD. Anti-VEGF therapy: comparison of current and future agents. Eye. 2008;22(10):1330-1336.
21. Uy HS, Chan PS, Ang RE. Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome. Cornea. 2008;27(1):70-73.
22. Kim TI, Kim SW, Kim S, et al. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea. 2008;27(3):349-352.
23. Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol. 2007;91(6):804-807.
24. Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology. 2008;115(6):e33-e38.
25. DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol. 2007;125(6):834-836.
26. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea. 2008; 27(2):142-147.
27. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, non-comparative study. Arch Ophthalmol. 2009;127(4):381-389.
28. Cursiefen C, Masli S, Ng TF, et al. Roles of thrombospondin-1 and-2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci. 2004;45(4):1117-1124.
29. Sonoda Y, Streilein JW. Orthotopic corneal transplantation in mice-evidence that the immunogenetic rules of rejection do not apply. Transplantation. 1992;54(4):694-704.
30. Bock F, Onderka J, Hos D, et al. Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts. Exp Eye Res. 2008;87(5):462-470.
31. Blacher S, Detry B, Bruyere F, et al. Additional parameters for the morphometry of angiogenesis and lymphangiogenesis in corneal flat mounts. Exp Eye Res. 2009;89(2):274-276.
32. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87(12):1479-1488.
33. Huang AJ, Watson BD, Hernandez E, Tseng SC. Induction of conjunctival transdifferentiation on vascularized corneas by photothrombotic occlusion of corneal neovascularization. Ophthalmology. 1988;95(2):228-235.
34. Yoeruek E, Ziemssen F, Henke-Fahle S, et al. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol. 2008;86(3):322-328.
35. Bock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci. 2007;48(6):2545-2552.
36. Yu L, Wu X, Cheng Z, et al. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci. 2008; 49(2):522-527.
37. Papathanassiou M, Theodossiadis PG, Liarakos VS, et al. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol. 2008;145(3):424-431.
38. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12(4):242-249.
39. Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2006;104:264-302.
40. Dana MR, Zhu SN, Yamada J. Topical modulation of interleukin-1 activity in corneal neovascularization. Cornea. 1998;17(4):403-409.
41. The Australian Corneal Graft Registry 2007 Report. Adelaide, South Australia: Flinders University Press; 2007.
42. Hill JC. The relative importance of risk factors used to define high-risk keratoplasty. Ger J Ophthalmol. 1996;5(1):36-41.
43. Khodadoust AA. The allograft rejection: the leading cause of late graft failure of clinical corneal grafts. In: Porter R, Knight J, eds. Corneal Graft Failure. Amsterdam: Elsevier; 1973.